Proffitt & Goodson’s AstraZeneca AZN Stock Holding History

Proffitt & Goodson’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-8	Closed	-$1K	–	260
2020 Q3	$1K	Buy	+8	New	+$890	﹤0.01%	264

Other funds holding AZN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Proffitt & Goodson's AZN Position: Q4 2020 in Review

Proffitt & Goodson sold out of AstraZeneca (AZN) in Q4 2020, closing a stake of 8 shares — an estimated $1K sold.

Proffitt & Goodson first reported a position in AZN in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 787 funds tracked by Wall St. Rank hold AZN as of Q4 2020.

Proffitt & Goodson reported no remaining AstraZeneca position as of Q4 2020 after selling out during the quarter.
Proffitt & Goodson sold 8 AstraZeneca shares in Q4 2020, an estimated $1K.
Proffitt & Goodson first reported a position in AstraZeneca in Q3 2020 and held it in 1 quarter.
Proffitt & Goodson's AstraZeneca position peaked at $1K in Q3 2020.
787 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2020.

Based on Proffitt & Goodson's 13F filing for Q4 2020, filed 25 Jan 2021.